BALA CYNWYD, Pa., March 31, 2015 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of Hyperion
Therapeutics, Inc. ("Hyperion" or "the Company") (Nasdaq: HPTX) for
possible breaches of fiduciary duty and other violations of state
law in connection with the sale of the Company to Horizon Pharma
plc. ("Horizon").
Click here to learn more about the investigation
http://brodsky-smith.com/911-hptx-hyperion-therapeutics-inc.html,
or call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Hyperion shareholders will
receive only $46.00 in cash for each
share of Hyperion stock they own. The investigation concerns
whether the Board of Hyperion breached their fiduciary duties
to stockholders by failing to adequately shop the Company before
agreeing to enter into this transaction, and whether Horizon is
underpaying for Hyperion. The transaction may undervalue Hyperion
which manufactures the drug Ravicti, a treatment for Urea Cycle
disorder. The FDA approved Ravicti in 2013 and the drug has annual
sales of $105 million. However,
Hyperion has estimated that Urea Cycle disorder is substantially
under diagnosed providing ample room for growth. As a result,
an analyst has set a $52.00 per share
price target for Hyperion stock and following the announcement
Horizon stock was up 18%.
If you own shares of Hyperion stock and wish to discuss the
legal ramifications of the investigation, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith,
LLC, Two Bala Plaza, Suite 510, Bala
Cynwyd, PA 19004, by visiting
http://brodsky-smith.com/911-hptx-hyperion-therapeutics-inc.html,
or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and class action lawsuits. The attorneys at Brodsky
& Smith have been appointed by numerous courts throughout the
country to serve as lead counsel in class actions and have
successfully recovered millions of dollars for our clients and
shareholders. Attorney advertising. Prior results do not guarantee
a similar outcome.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert--brodsky--smith-llc-announces-investigation-of-the-board-of-directors-of-hyperion-therapeutics-inc---hptx-300059015.html
SOURCE Brodsky & Smith, LLC